Filter based on tags
Filter based on tags
Show all Asthma / Allergy Biobanking Data Management Platform Chronic Obstructive Pulmonary Disease (COPD) COVID-19 Cystic Fibrosis (CF) Diffuse Parenchymal Lung Disease (DPLD) DZL Academy End-Stage Lung Disease Event DZL Academy Imaging Platform Lung Cancer (LC) Pneumonia and Acute Lung Injury Prizes and Awards Pulmonary Hypertension (PH)
Fibrocytes are bone marrow-derived cells that have been shown to be important for wound healing. Yet, another role of fibrocytes has now been identified by scientists from the German Center for Lung Research, working at...
This year's ERS Award for "Lifetime Achievement in Basic and Translational Sciences" goes to Rachel C. Chambers, a member of the DZL's International Scientific Advisory Board.
International research team reveals key mechanisms of scarring in Long-COVID and validates new progression biomarkers.
Prof. Marcus Mall is Global Winner 2022 in the Life Sciences category of the Falling Walls Foundation.
DZL scientists have investigated the role of age and the disease severity for the health status and prognosis of COPD patients.
Asthma: Results from the ALLIANCE registry could help detect inflammation in the small airways more easily in the future.
A large number of people are currently contracting COVID-19. Fortunately, most of them are experiencing only mild symptoms, largely thanks to the high vaccination rate. However, in some individuals the disease takes a much more...
Earlier treatment means disease progression is likely to be significantly slowed.
Under the direction of the BREATH scientist Prof. Dr. Burkhard Tümmler, the second edition of the monograph „Mutation-specific therapies in cystic fibrosis“ has now been published.
In a rare form of lung cancer, new molecular findings create the prerequisite for better understanding and therapeutic advances.
With triple therapy, the lungs of cystic fibrosis patients are better ventilated down to their most minor ramifications.
Lung transplantation is an established therapy option for children and young people with serious and progressive lung diseases without any other alternative treatment.
asterisk search close arrow-circle-o-down linkedin-square bars ellipsis-v youtube-square instagram envelope-square chevron-down
You can find more information on this in our
OK, please proceed